A Phase 2, Multicenter, Randomized Open-Label Study to Determine the Efficacy of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma.

Trial Profile

A Phase 2, Multicenter, Randomized Open-Label Study to Determine the Efficacy of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Chlorambucil; Cytarabine; Fludarabine; Fludarabine; Gemcitabine; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SPRINT
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 03 Aug 2018 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
    • 28 Jul 2018 This trial has been completed in Germany, according to European Clinical Trials Database.
    • 24 Apr 2018 Planned End Date changed from 28 Mar 2018 to 5 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top